Bio-Rad Laboratories Class A
440 hedge funds and large institutions have $5.41B invested in Bio-Rad Laboratories Class A in 2024 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 135 increasing their positions, 180 reducing their positions, and 80 closing their positions.
5.29% more ownership
Funds ownership: 79.21% → 84.5% (+5.3%)
6% less funds holding
Funds holding: 467 → 440 (-27)
16% less capital invested
Capital invested by funds: $6.42B → $5.41B (-$1.01B)
25% less first-time investments, than exits
New positions opened: 60 | Existing positions closed: 80
25% less repeat investments, than reductions
Existing positions increased: 135 | Existing positions reduced: 180
45% less funds holding in top 10
Funds holding in top 10: 11 → 6 (-5)
47% less call options, than puts
Call options by funds: $6.94M | Put options by funds: $13.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VanEck Associates
New York
|
+$192M |
| 2 |
First Eagle Investment Management
New York
|
+$184M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$56.3M |
| 4 |
Select Equity Group
New York
|
+$39.2M |
| 5 |
EARNEST Partners
Atlanta,
Georgia
|
+$26.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
Southpoint Capital Advisors
New York
|
-$34.6M |
| 2 |
HP
Hound Partners
New York
|
-$29M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$25.2M |
| 4 |
BCM
Boone Capital Management
Atlanta,
Georgia
|
-$25M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$24.7M |
BIO Hedge Fund Activity: Q2 2024 in Review
440 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q2 2024, worth a combined $5.41B — down 16% from $6.42B a quarter earlier.
Sellers outnumbered buyers: 80 funds closed out of BIO and 60 opened new positions — a net loss of 20 holders — while 180 trimmed existing stakes and 135 added.
The largest buyer was VanEck Associates, opening a new position worth an estimated $192M. The largest seller was Southpoint Capital Advisors, exiting entirely with an estimated $34.6M sold.
- 440 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q2 2024, down from 467 in Q1 2024.
- Funds reported $5.41B of Bio-Rad Laboratories Class A stock for Q2 2024, down 16% quarter-over-quarter.
- 60 funds opened new Bio-Rad Laboratories Class A positions in Q2 2024 and 80 closed out, a net change of -20 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q2 2024 was VanEck Associates, an estimated $192M added.
- The largest Bio-Rad Laboratories Class A seller in Q2 2024 was Southpoint Capital Advisors, an estimated $34.6M sold.
Based on aggregated 13F filings for Q2 2024.